TOLERION, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2001-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.tolerioninc.com
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
Phase 2
Active, not recruiting
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Other: TOL-3021 PlaceboBiological: TOL-3021
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Tolerion, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT03895437
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸MedStar Health Research Institute, Hyattsville, Maryland, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
Diabetes AutoimmunitY Withdrawn in Established Patients (DAY)
Phase 2
Withdrawn
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Biological: TOL-3021Other: TOL-3021 Placebo
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Tolerion, Inc.
- Registration Number
- NCT03794960
Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)
Phase 2
Withdrawn
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Other: TOL-3021 PlaceboBiological: TOL-3021
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Tolerion, Inc.
- Registration Number
- NCT03794973
- Locations
- 🇺🇸
University of Miami Diabetes Research Institute, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath